{"id":5760,"date":"2025-09-30T07:49:23","date_gmt":"2025-09-30T05:49:23","guid":{"rendered":"https:\/\/www.probeltepharma.es\/2025\/09\/30\/publication-of-findings-on-subcutaneous-immunotherapy-in-the-paediatric-population\/"},"modified":"2025-09-30T07:49:23","modified_gmt":"2025-09-30T05:49:23","slug":"publication-of-findings-on-subcutaneous-immunotherapy-in-the-paediatric-population","status":"publish","type":"post","link":"https:\/\/probeltepharma.es\/en\/2025\/09\/30\/publication-of-findings-on-subcutaneous-immunotherapy-in-the-paediatric-population\/","title":{"rendered":"Publication of findings on subcutaneous immunotherapy in the paediatric population"},"content":{"rendered":"

On 12 June, a study on the Beltavac\u00ae preparation was published in the Journal of Clinical Medicine, demonstrating the efficacy and good safety profile of subcutaneous immunotherapy in paediatric patients with allergic rhinitis caused by house dust mites. <\/p>\n

This development supports the scientific evidence on allergen immunotherapy and is a further step in innovation in healthcare for young patients. The study further confirms that Beltavac\u00ae is a safe and effective therapeutic option in the paediatric population. <\/p>\n

The full article can be found at the following link: https:\/\/lnkd.in\/dkfVMdRy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

On 12 June, a study on the Beltavac\u00ae preparation was published in the Journal of Clinical Medicine, demonstrating the efficacy […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[966],"tags":[],"class_list":["post-5760","post","type-post","status-publish","format-standard","hentry","category-industry-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t